Observational research links liver-derived factors to muscle loss in chronic liver disease, suggesting new therapeutic targets.
Elevated C-BAs may represent a critical, liver-derived humoral factor associated with the pathological features of liver-related sarcopenia. C-BA-associated muscle mass loss and systemic inflammation are reflected at the molecular level by a shift toward a slow-twitch phenotype, accumulation of macrophages and altered energy metabolism in muscle biopsies. These findings suggest that C-BAs may serve as a potentially actionable therapeutic target for mitigating muscle catabolism and improving clinical outcomes in CLD patients.
No takes yet. Share an insight, caveat, or question.
Iwasa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: